MIT research shows positive results of skin patch for cancer treatment
Category: #research  By Nikita Chaurasia  Date: 2019-08-26
  • share
  • Twitter
  • Facebook
  • LinkedIn

MIT research shows positive results of skin patch for cancer treatment
  • The skin patch designed, demonstrated positive results in an experiment on mice and human skin samples.
  • The MIT researchers designed the patch to fight melanoma cancer.

Researchers at the Massachusetts Institute of Technology reportedly announced successful results of a skin patch developed to offer cancer treatment in mice & human skin samples at the American Chemical Society conference in California, San Diego.

Apparently, the researchers at the MIT designed the patch to fight melanoma, a fatal but treatable skin cancer. For the uninitiated, Melanoma is subjected to be caused by an extreme exposure to UV rays from the sun or other sources. It has been claimed that the patch is less than a centimeter long and covered with a gluey film, which allows it to be applied and detached from the skin within a minute.

As per trusted reports, the researchers of the organization used the patch to deliver a toxin in healthy mice and later compared the immune response to other treatment methods used to vaccinate against the flu and measles. The results of the skin patch presented a robust antibody response along with a strong immune response in human skin.

The lead author of the study and HOD of Chemical Engineering, MIT, Dr. Paula Hammond reportedly stated that the organization’s recently designed patch technology can be used to offer vaccines to fight against various infectious diseases. Additionally, the researchers are pleased by the possibility of the patch to win against melanoma cancer.

The patch is embedded with microneedles, developed through a layer-by-layer coating process. This provides the advantage over syringes for its painless, easy to administer and reduced infection risk characteristics.

The researchers claimed that the patch treatment produced over 9 times the level of infection-fighting antibodies while comparing to the intramuscular injections. Additionally, it also produced over 160 times the level of antibodies compared to subcutaneous injections.

Speculation has it that the research was aided by the U.S. Department of Defense along with the Koch Institute for Integrative Cancer Research at MIT and Singapore-MIT Alliance for Research and Technology.

Source credit: https://www.cnbc.com/2019/08/25/new-skin-patch-to-deliver-cancer-medicine-shows-promise-in-mice-mit-scientists-say.html

About Author

Nikita Chaurasia    

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

Google to settles fiscal fraud probe with French authorities
Google to settles fiscal fraud probe with French authorities
By Nikita Chaurasia

The company has decided to pay 1 billion euros to the French regulators, considerably less than the 1.6 billion euros that it had to pay for the raid in 2016. Google LLC, a multinational tech company that offers internet-related services, has decid...

TrakCel & McKesson partner to help commercialize gene & cell therapy
TrakCel & McKesson partner to help commercialize gene & cell therapy
By Nikita Chaurasia

The combination of these two product suites is designed specifically for the growing number of developers that are nearing the commercial launch of gene and cell therapies. The integrated platform allows the product scale-up towards market deliver...

TOI & CareMore care model showcases better cancer care at lower cost
TOI & CareMore care model showcases better cancer care at lower cost
By Nikita Chaurasia

The study registered CareMore patients that were newly diagnosed with hematologic and solid malignancies from November 2016 to September 2018.   The cancer care model which is value-based used LHWs, they are non-physician community members w...